Last reviewed · How we verify
Aspirin and clopidogrel / Prasugrel
Aspirin and clopidogrel / Prasugrel is a Antiplatelet agent (dual therapy combination) Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently FDA-approved for Acute coronary syndrome (ACS) with percutaneous coronary intervention (PCI), Secondary prevention of stent thrombosis post-PCI, Stable coronary artery disease with stent placement.
Aspirin and clopidogrel/prasugrel are antiplatelet agents that inhibit platelet aggregation through different pathways to prevent thrombotic events.
Aspirin and clopidogrel/prasugrel are antiplatelet agents that inhibit platelet aggregation through different pathways to prevent thrombotic events. Used for Acute coronary syndrome (ACS) with percutaneous coronary intervention (PCI), Secondary prevention of stent thrombosis post-PCI, Stable coronary artery disease with stent placement.
At a glance
| Generic name | Aspirin and clopidogrel / Prasugrel |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Antiplatelet agent (dual therapy combination) |
| Target | COX-1 (aspirin); P2Y12 receptor (clopidogrel/prasugrel) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Aspirin irreversibly inhibits cyclooxygenase (COX), reducing thromboxane A2 production and platelet aggregation. Clopidogrel and prasugrel are P2Y12 receptor antagonists that block ADP-mediated platelet activation. The combination provides dual antiplatelet therapy (DAPT) to reduce stent thrombosis and recurrent ischemic events.
Approved indications
- Acute coronary syndrome (ACS) with percutaneous coronary intervention (PCI)
- Secondary prevention of stent thrombosis post-PCI
- Stable coronary artery disease with stent placement
Common side effects
- Bleeding (major and minor)
- Dyspepsia
- Gastrointestinal hemorrhage
- Thrombotic thrombocytopenic purpura (TTP)
- Neutropenia
Key clinical trials
- Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI (PHASE4)
- The Switching Antiplatelet-9 (SWAP-9) Study (PHASE4)
- Bariatric Surgery for the Reduction of cArdioVascular Events Randomized Controlled Trial (NA)
- Aspirin and a PoTent P2Y12 Inhibitor Versus Aspirin and Clopidogrel in Patients Undergoing PCI for Complex Lesion (PHASE4)
- STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT (NA)
- Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38) (NA)
- PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy (NA)
- A Polypill for Acute Coronary Syndrome (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aspirin and clopidogrel / Prasugrel CI brief — competitive landscape report
- Aspirin and clopidogrel / Prasugrel updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI
Frequently asked questions about Aspirin and clopidogrel / Prasugrel
What is Aspirin and clopidogrel / Prasugrel?
How does Aspirin and clopidogrel / Prasugrel work?
What is Aspirin and clopidogrel / Prasugrel used for?
Who makes Aspirin and clopidogrel / Prasugrel?
What drug class is Aspirin and clopidogrel / Prasugrel in?
What development phase is Aspirin and clopidogrel / Prasugrel in?
What are the side effects of Aspirin and clopidogrel / Prasugrel?
What does Aspirin and clopidogrel / Prasugrel target?
Related
- Drug class: All Antiplatelet agent (dual therapy combination) drugs
- Target: All drugs targeting COX-1 (aspirin); P2Y12 receptor (clopidogrel/prasugrel)
- Manufacturer: Assistance Publique - Hôpitaux de Paris — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Acute coronary syndrome (ACS) with percutaneous coronary intervention (PCI)
- Indication: Drugs for Secondary prevention of stent thrombosis post-PCI
- Indication: Drugs for Stable coronary artery disease with stent placement
- Compare: Aspirin and clopidogrel / Prasugrel vs similar drugs
- Pricing: Aspirin and clopidogrel / Prasugrel cost, discount & access